The company said initial efficacy results from a Phase I trial did not provide a competitive benefit-risk profile in CLDN18.2-positive gastric and gastroesophageal cancer.
NEW YORK – Everest Medicines said on Sunday that the US Food and Drug Administration cleared an investigational new drug application (IND) seeking permission to begin studying its mRNA vaccine EVM14 ...
The firm's Heart-2 study of VERVE-102, which is designed to inactivate the PCSK9 gene, is already underway in Canada and the UK.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback